Breaking News, Collaborations & Alliances

Boehringer Ingelheim and Autifony Enter Agreement

The potential value could reach €627.5 million

Boehringer Ingelheim and Autifony Therapeutics have signed an agreement regarding certain aspects of Autifony’s voltage gated potassium channel modulator platform. Boehringer Ingelheim now has an exclusive option to purchase the Kv3.1/3.2 positive modulator platform. Included in the agreement is the lead compound AUT00206, a novel, orally active small molecule that is currently being evaluated in two Phase Ib studies, including one in patients with schizophrenia.   Boehringer Ingelheim w...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters